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Background: Fetuin-A, an inhibitor of the insulin receptor phosphorilation, is associated with insulin resistance, metabolic syndrome (MetS) and 
early atherosclerosis. We hypothesized that plasma fetuin-A is independently associated with the presence of an atherogenic dyslipidemia and MetS 
in type-2 diabetes (T2DM).
Methods: A total of 608 subjects with T2DM (mean age 59.2 ± 9.3, 62.2% men) without advanced kidney disease, known cardiovascular disease 
or on insulin replacement therapy were included. MetS was defined based on the National Cholesterol Educational Program criteria. Insulin 
resistance was estimated using the homeostasis model assessment (HOMA-IR).
Results: Subjects in the higher fetuin-A tertile had an increased prevalence of MetS (78%) compared to 65 % in the lowest tertile. Fetuin A was 
inversely associated with HDL (B, -0.014, p<0.05), Lp(a) (B, -0.0352, p<0.05), and positively associated with triglycerides (B, 0.133, p=0.001), 
VLDL (B, 0 .0281, p<0.01), Apo A2 (B,0.007, p<0.01), Free Fatty Acids (B, 0.0002, p<0.005) and Apo C3 (B, 0.008, p<0.01). In a race, age and 
gender adjusted model a higher fetuin-A level increased the odds for MetS (OR 1.91, 95% CI 1.28-2.84), even after adjusting for HOMA-IR (OR 1.6, 
95% CI 1.03-2.7). In a multivariate model accounting for potential confounding variables (age, gender, race, serum albumin, adiponectin , hsCRP, 
kidney function, and medication use) fetuin-A levels increased by 10.3 ng/l (95% CI 3.0-17.5) for each additional MetS criteria present. In further 
adjustment for HOMA-IR, fetuin-A remained positively associated only with triglycerides (B, 0.1134, p<0.01), VLDL (B, .024, p<0.01), Apo A2 (B, 
0.007, p<0.01) and Apo C3 (B, 0.008, p<0.01). No association was noted with central adiposity, blood pressure, Apo B, Apo A1, hscrp, adiponectin or 
leptin
Conclusion: Among individuals with T2DM, fetuin-A is associated with the presence of MetS and atherogenic lipoproteins involved in the synthesis 
and catabolism of triglyceride rich particles independent of insulin resistance, inflammation or adipokines.
